These presentations will include clinical data, including recent analyses, from the core phase of the Company’s Phase IIb trial with MIN-101 as monotherapy for unmet needs in patients suffering from schizophrenia, particularly negative symptoms.
http://ir.minervaneurosciences.com/releasedetail.cfm?ReleaseID=993415
So they’ll be testing it as monotherapy.
Hope this drug make it to the market soon…!!!
Actually, they HAVE tested it as monotherapy. Sorry.
http://ir.minervaneurosciences.com/releasedetail.cfm?releaseid=972955
Positive symptoms were observed to remain stable,
I have no idea what that means.
Actually it probably follows on from this:
To participate in the trial, patients were required to have stable positive and negative symptoms for three months prior to entry.
Good news thanks!
How long does phase 3 usually take?
Wonder which negative symptoms it would even help. Hoping they discover treatments for anhedonia researching for MDD; that seems plausible.